GlassScriptPhysician profile
Ulrike Ziegner
NPI 1407867203
$28,985.35
in general payments reported to CMS, 2019-2025
38 companies · $2,780 in 2025
The $2,780 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,820 · 2020: $2,324 · 2021: $8,024 · 2022: $3,369 · 2023: $2,299 · 2024: $2,369 · 2025: $2,780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,413 · Education: $35.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,412.88 |
| Education | $35.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $5,514.76 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $4,866.21 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $3,321.17 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Genzyme Corporation | $2,962.97 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,822.34 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $1,305.62 | 2019-2025 | |
| Octapharma USA, INC. | $1,271.84 | 2020-2023 | Cutaquig |
| Amgen INC. | $1,252.04 | 2020-2025 | Tezspire, Actimmune |
| Regeneron Healthcare Solutions, INC. | $1,130.58 | 2019-2025 | Dupixent |
| Csl Behring | $1,034.83 | 2019-2025 | Hizentra, Haegarda |
| Grifols USA, LLC | $742.05 | 2022-2025 | Xembify |
| Novartis Pharmaceuticals Corporation | $593.57 | 2019-2025 | |
| Genentech USA, INC. | $572.27 | 2019-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $425.26 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $347.68 | 2019-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $283.80 | 2021-2024 | Opzelura |
| Ars Pharmaceuticals Operations, INC. | $237.51 | 2025 | Neffy |
| Abbvie INC. | $189.36 | 2022-2023 | Rinvoq |
| Optinose US, INC. | $170.61 | 2019-2025 | |
| Amarin Pharma, INC. | $125.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $91.99 | 2022 | |
| Covidien LP | $91.59 | 2019 | |
| Leo Pharma INC. | $90.23 | 2022-2025 | Anzupgo |
| Regeneron Pharmaceuticals, INC. | $87.27 | 2021-2024 | Dupixent |
| Blueprint Medicines Corporation | $63.01 | 2023 | Ayvakit |
| Galderma Laboratories, L.P. | $54.59 | 2025 | Nemluvio |
| Alk-Abello, INC | $45.18 | 2023 | Histamine Positive, Ragwitek, Grastek |
| Kaleo, INC. | $43.39 | 2021-2022 | |
| Lilly USA, LLC | $31.41 | 2025 | Ebglyss |
| Jazz Pharmaceuticals INC. | $30.78 | 2022 | |
| Ionis Pharmaceuticals, INC. | $26.20 | 2025 | |
| Merck Sharp & Dohme LLC | $25.86 | 2023 | |
| Genentech, INC. | $24.79 | 2019 | |
| Sobi, INC | $24.04 | 2019 | |
| Cycle Pharmaceuticals INC | $23.72 | 2025 | Sajazir |
| Biocryst Pharmaceuticals, INC. | $23.49 | 2020 | |
| Bio Products Laboratory USA, INC. | $20.94 | 2023 | Coagadex, Gammaplex |
| Paratek Pharmaceuticals, INC. | $17.40 | 2025 | Xhance, Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ulrike Ziegner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.